Law360 (May 10, 2005, 12:00 AM EDT) -- RNA interference technology initiates degradation of specific messenger RNA (mRNA) and prevents production of the protein which the mRNA encodes. This technology shows promise both for treating disease and creating models of disease. Now that the technology is generally known, can a company patent its own particular application?
As with all patent applications, the company must demonstrate that its RNA interference technology has utility, is adequately described in the specification of the patent application, and is both novel and nonobvious. The United States Patent and Trademark Office (the "Patent Office") has provided informal guidance on these issues in the context...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!